4576 D. Western Therapeutics Institute
- 82
- +2+2.50%
D. Western Therapeutics Institute News
D. Western Therapeutics Institute: Consolidated financial results for the six-month period ended June 30, 2024 (based on Japanese accounting standards).
D. Western Therapeutics Institute: Confirmatory letter.
D. Western Therapeutics Institute: Interim Report - 27th Period (2024/01/01 - 2024/12/31)
D. Western Therapeutics Institute: Second quarter financial results presentation materials for December 2024 fiscal year.
D. Western Therapeutics Institute: Financial statements for the second quarter (interim period) of the fiscal year ending December 2024, based on Japanese accounting standards (consolidated).
D. Western Therapeutics Institute: Announcements of monthly exercise status for the 12th subscription rights (with exercise price adjustment clause).
D. Western Therapeutics Institute: Change report.
D. Western Therapeutics Institute: Policy regarding the re-application of the nerve pain treatment drug "DW-5LBT".
D. Western Therapeutics Institute: Announcements of individual stocks: Notification of Receipt of Approval Notification for Neurological Pain Treatment Drug, DW-5LBT.
D. Western Therapeutics Institute: Change Report
D. Western Therapeutics Institute: Announcement of the mass exercise of the 12th subscription rights (with exercise price adjustment clause).
D. Western Therapeutics Institute: Announcements of monthly exercise status for the 12th subscription rights (with exercise price adjustment clause).
D. Western Therapeutics Institute: Change report.
D. Western Therapeutics Institute: Announcement of completion of acquisition and extinguishment of subscription rights for the 11th time.
D. Western Therapeutics Institute: Change Report (short-term mass transfer)
D. Western Therapeutics Institute: Interim report
D. Western Therapeutics Institute: Announcements of individual stocks regarding the completion of redemption of the first series of unsecured convertible bonds with subscription rights and the recording of special losses.
D. Western Therapeutics Institute: Report on a large shareholding
D. Western Therapeutics Institute: Notice regarding completion of payments relating to the issuance of unsecured corporate bonds (private placement bonds) and 12th stock acquisition rights (with exercise price correction clauses) through third-party allotment
D.WESTERN THERAPEUTICS INST: Notice regarding the redemption of the 1st unsecured convertible bonds with stock acquisition rights, the 11th acquisition and cancellation of stock acquisition rights, and the issuance of unsecured corporate bonds and the 12th stock acquisition rights through third party allotment
Analysis
Price Target
No Data
